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identification of TSC and its comorbid conditions are crucial 
for mitigating long-term negative outcomes in these patients. 
While TSC is more familiar to pediatricians, adult providers 
are much less trained to identify and treat this condition. 
Effective understanding is crucial for ensuring a stable con-
dition throughout the patient’s lifetime.
TSC is characterized by benign tumors that can develop 
on the brain, skin, heart, lungs, kidneys, and liver (1, 2). 
Symptoms and manifestations of this condition include 
facial/topical angiomyolipomas (AMLs), cardiac rhabdomy-
omas, brain subependymal giant cell astrocytoma (SEGA), 
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Tuberous sclerosis complex (TSC) is an autosomal domi-
nant inherited disease, characterized by lesions that involve 
multiple organs of the body and variable clinical manifesta-
tions. Although TSC shows dominant inheritance, 60–70% 
of patients are sporadic cases due to de novo mutation. TSC 
has an estimated incidence of ~1 in 5800 births, with preva-
lence rates of 1 in 7000–20,000. Currently, there are approx-
imately 2 million people who are believed to be affected by 
TSC worldwide, with approximately 40,000–80,000 patients 
in the United States (1). In spite of its relative rarity, the 
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not even fulfilling all the diagnostic criteria of TSC. There-
fore, these hereditary manifestations mostly show mutations 
to TSC1  (7). Figure 1 displays the downstream pathway of 
TSC1 and TSC2 dysregulation.
The TSC1 gene is composed of 23 exons, with 21 encoding 
hamartin (130 kDa). The TSC2 gene consists of 42 exons, 
with 41 encoding tuberin (180 kDa). Mutation detection 
efforts in TSC patients have found mutations in approx-
imately 85% of the patients studied (9, 10). Table 2 identi-
fies recommendations from the 2012 consensus conference 
on TSC that a physician can follow if  TSC is suspected in a 
patient. In order to clinically confirm the presence of TSC, 
major and minor features need to be present, as defined by 
the 2012 International TSC consensus conference, as shown 
in Table 3.
 The TSC genotype is one the strongest predictors of renal 
manifestation (12). TSC2 mutant patients typically display 
increased incidence and severity of angiomyolipomata and 
cysts compared to TSC1 mutant patients (11). While severe 
renal disease outcomes can occur in TSC1 mutants, these 
patients are significantly less likely to exhibit severe renal 
manifestations than those with TSC2 mutation. Gener-
ally, patients who have no identified mutations (NIM) show 
syndromic manifestations that are less severe than patients 
with known mutations, especially in terms of cognitive and 
seizure symptoms. Furthermore, it has been observed in a 
systemic analysis by Seyam et al. that there is a higher fre-
quency of AML manifestations in patients with NIM than 
those with TSC1 mutations. These differences have not been 
observed between NIM and TSC2 (13). These findings sug-
gest that the renal manifestation of patients with NIM most 
closely resemble that of TSC2 instead of TSC1. This could 
be due to a defect in TSC2 that’s transcriptional, transla-
tional, or post-translational in nature. In addition, these 
patients warrant a closer examination of the TSC2 sequence 
and the effect that protein activity may have in NIM patients. 
The correlation between gender and renal manifestation 
is seemingly only significant for AML appearance (14). 
lymphangiomyomatosis, retinal astrocytic renal AML, and 
renal cell carcinoma (RCC). In addition to these conditions, 
neurologic conditions are especially prevalent in the form of 
mental stunting, autism, and epilepsy. Renal manifestations, 
in particular, are important to monitor, as they are found to 
be the number one cause for mortality in TSC patients, par-
ticularly due to malignant renal AMLs and RCC in younger 
patients (3). While neurological, renal, and cutaneous mani-
festations are the most common, the significance and severity 
can vary across individuals. Furthermore, the onset of TSC 
can take several years to manifest. As a genetic condition, 
TSC is a lifelong condition and requires regular monitoring 
of patients to ensure that tumor growth or new symptoms 
are identified as early as possible (3, 4). While this manu-
script focuses on renal manifestations, Table 1 outlines the 
frequency and symptoms of TSC manifestations in other 
systems of the body. The multiorgan onset of conditions 
necessitates the cooperation of multiple specialty providers 
to get the best possible outcomes for the patient.
 The genetic mechanism behind this condition results from 
a mutation to either the TSC1 gene on chromosome 9 or the 
TSC2 gene on chromosome 16 (5, 6). Two-thirds of the cases 
occur sporadically and are caused by new mutations. Within 
families with multiple afflicted members, about half  of the 
patients have shown linkage to locus 9q34 with the other half  
to 16p13 (7). Physiologically, these proteins are involved in 
the regulation of cell growth through the phosphatidylinosi-
tol 3-kinase signaling pathway (PI3K), an inhibitor of the 
mammalian target of rapamycin (mTOR). Mutations in the 
genes encoding these proteins cause the permanent activation 
of the mTOR pathway, leading to uncontrolled cellular pro-
liferation and formation of hamartomas in various organs of 
the body. Genetic mutation in TSC can lead to the deletion, 
rearrangement, or inactivation of the TSC1 or TSC2 genes. 
While hereditary germline mutations are observed, major-
ity of TSC patients (70%) express the condition through 
somatic mutations (8). Familial transmission, more com-
monly, has less severe manifestations of the disease, at times 
Table 1: The manifestations of tuberous sclerosis complex and the percentages of distribution.
Type Percentage Description
Cutaneous 90 Skin lesions in all ages
Renal 80 #1 Morbidity/Mortality: kidney function, hemorrhage, cysts, carcinoma 
Neurological 70–90 #2 Morbidity & Mortality: epilepsy, seizures, autism, mental retardation
Ophthalmologic 30–50 Retinal hamartoma, bilateral and multiple, no visual impairment
Pulmonary 40 Cysts, smooth muscle, mainly adult females, reduced pulmonary function
Cardiac 80 Rhabdomyoma, mainly fetus and newborn, cardiomegaly, murmurs 
Adapted from Schepis C. The tuberous sclerosis complex. Dermatol Cryosurg Cryother. 2016;615–17. (1).
Renal manifestation in TSC
 Journal of Kidney Cancer and VHL 2020; 7(3): 5–19 7
Table 2: Recommendations for physicians for potential TSC 
diagnosis.
Genetic 
Offer genetic testing for the families in situations where 
TSC diagnosis cannot be confirmed clinically. 
Obtain genetic family history in order to identify other 
members who may be at risk.
Kidney 
Order MRI to screen for the presence of 
angiomyolipoma and renal cysts in the abdominal 
region.
Screen for hypertension from clinical blood pressure 
readings.
Monitor proper renal function by determination of 
glomerular filtration rate (GFR).
Adapted from Krueger DA, Northrup H, International Tuberous 
Sclerosis Complex Consensus Group. Tuberous sclerosis complex 
surveillance and management: Recommendations of the 2012 
International Tuberous Sclerosis Complex Consensus Conference. 
Pediatr Neurol. 2013;49(4):255–65. http://dx.doi.org/10.1016/j.
pediatrneurol.2013.08.002. (11).


















Figure 1: Normal downstream pathway of TSC1 and TSC2, 
and its gene products. These proteins are involved in the 
regulation of cell growth through the phosphatidylinosi-
tol 3-kinase signaling pathway (PI3K), an inhibitor of the 
mammalian target of rapamycin (mTOR). TSC1: tuberous 
sclerosis complex 1; TSC2: tuberous sclerosis complex 2; 
Rheb: Ras homolog enriched in brain; GTP: Guanosine tri-
phosphate; Raptor: regulatory-associated protein of mTOR; 
mLST8: target of rapamycin complex subunit LST8; mTOR: 
mammalian target of rapamycin.
Female  patients display a higher frequency of AMLs than 
males potentially due to the presence of increased estrogen 
and progesterone receptors on tumors. In addition, a large, 
double-blind study showed that females have an increased 
incidence of adverse outcomes from angiomyolipomata 
(15, 16). Furthermore, renal AMLs are found in larger quan-
tities and have larger volumes in women, compared to men. 
This suggests a hormonal effect on AML development and 
growth; this can also occur in prepubertal girls, who have 
higher estradiol levels than boys (17).
Pathophysiology
Angiomyolipoma
Renal AMLs are the most common benign tumors observed 
in TSC patients. The presentation of AMLs has been 
reported in 75–85% of TSC patients with renal lesions and 
in 49–60% of TSC patients, overall (3, 18). AMLs derive 
from the PEComa family of tumors, exhibiting immunore-
activity for both melanocytic markers (HMB-45 and mela-
nin-A antibodies) and smooth-muscle markers (actin and 
desmin). AMLs are composed of abnormal blood vessels, 
immature smooth-muscle cells, and fat cells, although the 
proportions can vary between lesions within the same kid-
ney (15). Presumably, this deficiency disrupts the integrated 
control of cell growth, leading to the AML (6). These tumors 
then arise by clonal proliferation of epithelioid cells distrib-
uted around blood vessels and, in patients with TSC, include 
renal AMLs and pulmonary lymphangioleiomyomatosis 
(LAM)  (19). A  neural crest cell origin has been proposed 
based on the co-expression of melanocytic and smooth cell 
markers, with two cell lineages known to arise, at least in 
part, from neural crest cells (20, 21). Re-expression of TSC2 
in an AML has shown to result in the maturation of AMLs 
into lymphatic endothelial cells (21). This has led many 
investigators to believe that AMLs do not actually arise 
from neural crest cells; instead, they may arise from the lym-
phatic endothelium  (22). Knocking-out TSC2 and Cdkn2a 
in the murine epithelial cell line gave rise to lesions that had 
some AML findings; however, an important caveat for these 
findings was that Cdkn2a encodes two proteins, p16 and 
p14ARK, and is associated with melanoma  (23). In some 
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studies, mesenchymal stem-cell-like cells have been identified 
in AMLs, and pericytes have been strongly implicated as the 
cell of origin for angiomyolipomata (4). These recent discov-
eries are interesting given the prevalence of vascular aneu-
rysms associated with TSC that arise in angiomyolipomata in 
the aorta and the brain (24–26). The lesions in AML express 
smooth-muscle actin and melanocyte markers, such as gp100, 
a splice variant of Pmel17, and even melanin A. Expression 
of these melanocyte-associated genes likely results from the 
mTOR-mediated increase in the microphthalmia (MITF/
TFE) family transcription factor activity (27). This increased 
MITF/ TFE transcription factor activity has caused con-
fusion between TSC-associated PEComas, the much more 
aggressive RCCs, and the PEComas associated with translo-
cations involving the TFE3 or TFEB transcription factors of 
the MITF/TFE family (28).
Cystic disease
Renal cysts have been observed in 14–32% of the TSC pop-
ulation and have predominately two types of manifestations. 
The most common presentation is either single or multiple 
small lesions, rarely symptomatic but in unison in their histol-
ogy. A less common cystic manifestation of TSC coexists with 
polycystic kidney disease, which indicates a poor prognosis 
for survival. The mTOR pathway is strongly associated with 
primary cilia-associated cystogenesis. Investigations of TSC1- 
or TSC2-associated renal cystic disease in mice have shown 
that cystogenesis can be attributed to specific nephron seg-
ments. Furthermore, all tubular segments have been found to 
be involved in murine TSC cyst formation (29). Incongruous 
findings have been attributed to tubular epithelial dedifferen-
tiation, a repair/regeneration process that recapitulates renal 
development (30). In mouse models studied, there seems to be 
significant elevation of cyst mTORC1 activity (phospho-S6 
expression) but a very low percentage of cells exhibiting loss 
of TSC expression (27). The somatic mutation (second hit) 
dogma of TSC renal disease is difficult to reconcile with the 
early investigations that failed to find loss of heterozygosity 
in a majority of cysts, indicating that TSC locus integrity is 
preserved in most renal cysts (31). The low percentage of cysts 
with loss of heterozygosity is similar to human TSC renal 
cystic disease, because human cysts also continue to express 
tuberin and hamartin, in contrast to the mechanism for angi-
omyolipomata, which show an inactivating mutation and loss 
of heterozygosity, resulting in the loss of tuberin staining (32). 
The low percentage heterozygosity loss has also been seen in 
PKD1-associated autosomal dominant polycystic kidney dis-
ease (ADPKD), suggesting that cystic disease may possibly 
represent a novel disease mechanism (29).
Autosomal dominant polycystic kidney disease
ADPKD accounts for fewer than 2% of TSC cases (33, 34). 
The phenotypic intersection between TSC and ADPKD 
cases indicate the existence of a functional relationship 
between the respective genes that have been recently identi-
fied as the mTOR signal pathway (35). Under normal con-
ditions, polycystin-1 and the TSC1/TSC2 tumor suppressor 
genes inhibit the function of mTOR, contributing to the 
suppression of cell replication at the G1-phase and subse-
quently resulting in apoptosis. The tuberin protein traffics 
polycystin-1 to the plasma membrane, which may be the 
fundamental basis for their genetic collaboration (36). TSC 
may therefore coexist with ADPKD in the same patient as a 
by-product of concurrent germline deletion of both PKD1 
and TSC2 genes (37). Approximately, 75% of TSC patients 
are from the pediatric age range (38).
Patients with an omission of both the PKD1 and TSC2 
gene advance to a premature and radical onset of PKD. 
Table 3: Necessary features for diagnosing TSC.
 Major features 
Dermatological • hypomelanotic macules (≥3, at 
least 5 mm diameter),
• angiofibroma (≥3 )
• ungual fibromas (≥2)
• shagreen patch
Ophthalmological • Multiple retinal hamartomas
• Cortical dysplasias*
Neurological • Subependymal nodules
• Subependymal giant cell 
astrocytoma
Cardiothoracic Cardiac rhabdomyoma
Pulmonary • Lymphangioleiomyomatosis 
• Angiomyolipomas (≥2)
Renal Angiomyolipomas (≥2) 
Minor features 
Dermatological • “Confetti” skin lesions
• Dental enamel pits (>3)
• Intraoral fibromas (≥2)
Renal Multiple renal cysts
Endocrine Nonrenal hamartomas
Adapted from Krueger DA, Northrup H, International Tuberous 
Sclerosis Complex Consensus Group. Tuberous sclerosis complex 
surveillance and management: Recommendations of the 2012 
International Tuberous Sclerosis Complex Consensus Conference. 
Pediatr Neurol. 2013;49(4):255–65. http://dx.doi.org/10.1016/j.
pediatrneurol.2013.08.002. (11).
TSC, Tuberous sclerosis complex.
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associated proteins (25). There is additional evidence to 
show that the coordinated activity of tuberin, polycystin, 
and mTOR, and its dysregulation has contributed to the 
expansion of renal cysts (45). Loss of regulatory properties 
of β-catenin is additionally linked to the renal cystic changes 
in VHL and TSC patients (46, 47). Renal complications 
in these patients mandate follow-up with regular physical 
exam, radiological imaging, and laboratory tests. Identifica-
tion and appropriately diagnosing each condition are para-
mount to ensuring the best possible outcomes for patients. 
Furthermore, increased information regarding the signaling 
pathways has commenced clinical trials for various pharma-
cological therapies (48–51).
Malignant tumors
Malignant AMLs and RCCs
In spite of the characteristic presence of benign tumors, the 
risk of malignant tumors is relatively low in TSC patients. 
Malignant tumors are seen in approximately 3% of patients 
and can be diagnosed as RCC or malignant epithelioid AML. 
These tumors develop at an average age of 36 years, 20 years 
earlier than the average age of onset (52). RCC accounts for 
2–3% of all adult malignancies and is the most common type 
of kidney cancer (52). There are a significant variety of his-
tologies with regard to RCC in TSC. The two main catego-
ries include clear cell RCC (ccRCC, ~85%) and nonclear cell 
RCC (nccRCC, ~15%). Both limited pathological data and 
overlapping physiology with fat-poor AMLs have inhibited 
the ability to elucidate the entire picture. Few RCCs in TSC 
patients show simultaneous expression of melanocytic and 
renal tubular markers and as such contribute to the heteroge-
neity of the tumors seen (53). Given the absence of the VHL 
gene in the majority of TSC patients, these types of RCCs 
develop independently of the canonical pathways (53). In 
TSC, drivers of RCC include loss-of-function mutations of 
TSC1/TSC2 genes that lead to the inactivation of the TSC 
signaling pathway (54). Malignant AMLs also have varied 
presentations in TSC, leading to confusion during diagnosis 
between epithelioid AMLs and RCC. The use of immunocy-
tochemical staining specific for cytokeratin and HMB-45 can 
help distinguish between the two (54).
Clinical manifestation
AMLs are detectable at a younger age in patients with TSC2 
mutations compared to patients with TSC1 mutations (13 
years vs. 24 years), and intervention is more often needed in 
patients with TSC2 mutations compared to those with TSC1 
mutations (27% vs. 13%) (17). Throughout the first few years of 
life, there is a progressive enlargement of the tumors with expe-
dited growth during adolescence and/or early adulthood, fol-
lowed by a decreased growth in 30% of elderly patients. AMLs 
are the primary reason for the morbidity and mortality seen in 
The  disease aggression might be a consequence of trans-
formed gene expression by microRNAs as a product of con-
vergent transcription of genes on the unaffected allele (39). 
Cyst formation in TSC patients with ADPKD ensues 
through a two-hit tumor suppressor mechanism, with loss of 
heterozygosity, particularly in the epithelial cells lining the 
cyst wall (30, 40). ADPKD patients with TSC usually present 
with abdominal distension or secondary hypertension and in 
some cases with hematuria secondary to the rupture of the 
cysts (40). These patients have an advanced risk of progres-
sion to end-stage renal disease ESRD beginning around 30 
years of age (41). In a study by Sampson et al., the authors 
demonstrated that cases with deletions in TSC1/PKD2 have 
enlarged cystic kidneys during infancy or childhood with fea-
tures of advanced ADPKD at the time of diagnosis (42).
Phenotypical overlap of VHL to TSC
While TSC and Von Hippel-Lindau disease (VHL) are caused 
by mutations in different genes, they show phenotypical and 
possible pathophysiological similarities. Both conditions 
are autosomal dominant disorders, characterized by solid 
and cystic renal pathologies due to mutations in the tumor 
suppressor genes. Both syndromes are also characterized 
by highly vascularized tumors, although RCCs are rarer in 
TSC than in VHL. The phenotypic expression of these con-
dition ensues when there is an inherited deactivating muta-
tion in the TSC1/TSC2 gene for TSC or the VHL gene for 
VHL syndrome, combined with an additional somatic muta-
tion in the affected locus. Even though TSC and VHL are 
the end result of two distinct mutations, they have certain 
resemblances with regard to their molecular pathogene-
sis (43). TSC and VHL disease are both diverse tumor sup-
pressor syndromes that have some common renal phenotypic 
features, including cysts and vascular tumors such as RCC. 
These resemblances may be the terminal consequences of 
intersection in signaling and gene expression effectors, such 
as primary cilia, vascular endothelial growth factor (VEGF), 
and β-catenin. The neoplasms in VHL display excessive 
production of messenger ribonucleic acid specific to hypox-
ia-inducible  factor (HIF)-dependent growth factors, such 
as VEGF, and this additional activity of VEGF and other 
hypoxia-inducible genes contribute to the development of 
neoplasms in TSC (43). TSC is characterized by unwarranted 
production of HIF factors while VHL includes suppression 
of proteasome-facilitated elimination of HIF  (44). Tuberin 
independently regulates VEGF activity via mTOR-depen-
dent and independent mechanisms. Loss of tuberin acceler-
ates upregulation of VEGF, which elucidates the exceedingly 
vascularized nature of these neoplasms seen in TSC (44). 
Both diseases have a concrete association with the develop-
ment of renal cystic disease, and it has been observed that 
renal cysts are attributed to mutations in the cilia and the 
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Table 4: Diagnosis and treatment of angiomyolipoma.
Size Characteristic Treatment/monitoring 
Small (<4 
cm)




Highly variable in behavior with the 
propensity to either grow quickly or 
remain benign. 
Due to their variable nature, more frequent images should be 
taken. To preserve renal function, preventative treatment by mTOR 
inhibitors should be taken. 
Large  
(>8 cm)
Most likely to be symptomatic; 
largest risk for malignancy and 
vascularization, leading to increased 
risk of hemorrhage. 
Once observed, elective treatment should be taken immediately to 
reduce the chance of symptoms and complications developing. If  no 
immediate risk of hemorrhaging presents itself, mTOR inhibitors 
should be taken to reduce the mass and the volume of the lesion. 
Adapted from Dickinson M, Ruckle H, Beaghler M, Hadley HR. Renal angiomyolipoma: Optimal treatment based on size and symptoms. 
Clin Nephrol. 1998 May;49(5):281–6. (21).
mTOR, mammalian target of rapamycin.
TSC patients, in spite of many being asymptomatic (17). When 
present, clinical manifestations include hemorrhage, leading to 
hematuria and loss of kidney function, with a greater risk of 
hemorrhage in tumors larger than 30 mm in size.
Symptomatic kidney cysts are seen in 30–50 % of TSC 
patients with renal manifestations. These are more frequently 
seen in patients with TSC2 mutations, compared to those with 
TSC1 mutations (55). AMLs that are sporadic and less than 2 
cm are of little clinical relevance and are not associated with 
decline in renal function (56). When AMLs are numerous and 
actively growing, the risk of renal dysfunction is increased, 
especially in approximately 3% of TSC patients with a contig-
uous gene syndrome affecting the TSC2 and PKD1 genes (57). 
Recommendation on treatment and monitoring of different 
sized AML by Dickinson et al. is illustrated in Table 4 (19). 
In these cases, renal cysts can develop early with the clinical 
course of renal function resembling that of ADPKD patients 
with ESRD in the second or third decade of life (58).
The most common clinical manifestations of symptomatic 
renal AMLs are the various forms of hemorrhage (intra-
tumoral, hematuria, or retroperitoneal hemorrhage) (59). 
The potential of developing these symptoms increases with 
increase in the size of the AML. Renal AMLs > 4 cm are 
more likely to grow and develop microaneurysms (43, 60). 
Likewise, the risk of significant hemorrhage is related to 
the degree of vascularity, the size of the AML, and the size 
of aneurysms within the AML. Increased vascularity and/
or aneurysm size (≥5 mm) are associated with an increased 
risk of rupture (24). Furthermore, the rate of growth should 
be monitored, with the most risk of hemorrhage in those 
enlarging at a rate of >30 mm (61).
The risk of bleeding can also increase during preg-
nancy due to hormonal changes and/or increased blood 
 volume  (62). Hormonal imbalances are potential causes 
for the increased rate of AML growth from infancy to 
adulthood. In contrast to the uniformly benign prognosis 
of classic renal AMLs, epithelioid variants may undergo 
malignant transformation, although this is quite infrequent. 
Malignant transformation can be manifested by both local 
recurrence and/or distal metastases. The relative risk is 
greater in patients with TSC, but most patients with malig-
nant transformation have sporadic renal AMLs (63, 64).
In a large-scale study of 164 pediatric patients with TSC, 
who underwent serial renal ultrasonography or computed 
tomography (CT), the authors found that the rate of renal 
AML increased up to an excess of 50% after the age of five 
with no renal AMLs in the first year of life (65). In another 
longitudinal study involving 60 children, rates of renal AMLs 
increased from 48% in boys and 60% in girls at a mean age 
of 6.9 years to 76% in boys and 83% in girls at follow-up 
at a mean age of 10.5 years (33). By the time these patients 
reached adulthood, 33% of the AMLs stopped growing (61).
The primary methods to diagnose the presence of AMLs 
are imaging technology, ultrasound (US), and magnetic res-
onance imaging (MRI) in the abdominal region (65). An 
example of a positive image is shown in Figure 2. However, 
cautious interpretation is warranted when considering these 
US data, as US often cannot detect fat-poor angiomyolipo-
mata, with approximately a third of patients demonstrating 
fat-poor lesions. Continued monitoring of renal AMLs is 
crucial, as they exhibit continued growth and patients may 
develop aneurysms as the AMLs enlarge. Increased size also 
leads to an increased risk of bleeding; AMLs > 3 cm and 
aneurysms ≥ 5 mm are associated with an increased risk of 
severe bleeding (61).
Fat poor AML
Nearly 5% of TSC-associated AMLs observed are fat-poor 
in nature. Containing an average of 4% fat by mass, these 
Renal manifestation in TSC
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Figure 2: Contrast enhanced CT images of abdomen in axial (a) and coronal (b) planes. This is the case of a 16-year-old female 
with tuberous sclerosis undergoing treatment with everolimus. The CT scan shows right heminephrectomy and an enlarged left 
kidney with multiple cysts and angiomyolipomas.
lesions often have similar tissue density as renal parenchyma, 
have the same echotexture as the kidneys, and are often not 
identified on US. The International Consensus Guidelines by 
the 2012 TSC consensus conference recommends the use of 
MRI for screening, as they are often missed in US (66). In 
addition, at least half  of the patients affected by TSC will 
have cystic disease on MRI, with it being common for some 
patients to have a solid mass associated with cystic compo-
nents. Such lesions should be serially measured and assessed 
for growth characteristics to help distinguish fat-poor AMLs 
from the malignant AMLs (67,68).
ADPKD
Polycystic kidney disease is characterized by the presence 
of an innumerable number of cysts that eventually occupy 
the renal parenchyma, culminating in renal failure and pre-
mature secondary hypertension. In most cases, diagnosis 
is established by utilizing clinical criteria; however, molec-
ular genetic testing can be utilized for prenatal diagnosis, 
for screening family members of affected individuals, and 
for cases where diagnosis is ambiguous. According to the 
kidney- related surveillance and management recommenda-
tions by the International Tuberous Sclerosis Complex Con-
sensus Group, MRI is the preferred modality for detection 
of renal cysts of ADPKD and TSC-associated AML, which 
is supplemented with frequent blood pressure screening and 
glomerular filtration rate (GFR) estimation (11). Renal US 
can be used to screen for AMLs and to monitor cysts; how-
ever, US can miss AMLs that are fat deprived or kidneys 
with numerous cysts. Thus, MRI of the kidneys may be pref-
erable for clearer images (69). Figure 3 shows how a positive 
image of renal cysts looks like on an US. Children >12 years 
and adults have higher potential of developing AML and, 
therefore, should undergo an MRI every 1–3 years. In cases 
of TSC where initial MRI has exclusively ruled out the pres-
ence of AML, annual follow-up with US is recommended 
with an MRI every 2–3 years (70). In addition, genetic test-
ing is recommended for TSC and ADPKD patients when 
they are presented with an ambiguous diagnosis (71, 72).
Cystic disease
TSC renal cystic disease is identified conventionally by MRI 
in approximately 50% of patients (73). The size of renal cysts 
in TSC renal disease can range from microscopic glomerulo-
cystic disease to the polycystic renal phenotype found in the 
TSC2/PKD1 contiguous gene syndrome. In most patients 
with TSC, renal cysts are asymptomatic with a limited num-
ber of cysts that are smaller (73, 74). However, similar to 
AML, their prevalence increases with age (33). These types 
of cysts do not require regular surveillance imaging, but 
images should still be taken, as these patients are at risk for 
AML as they age. The renal and nonrenal manifestations of 
cystic disease are outlined in Table 5.
Oncocytoma
Oncocytomas have been described in patients with TSC 
but seem to be generally rare and are almost always benign. 
Renal oncocytoma are histologically described as containing 
nests and tubular structures lined by cells with eosinophilic, 
granular cytoplasm (76). They are described as containing 
edematous myxoid or hyalinized stroma in some areas with 
tubular structures dispersed in the stroma. Clear cytoplasm 
may also be focally present with cells in lesions containing 
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Figure 3: Ultrasound imaging reveals that both kidneys are enlarged with multiple cysts and loss of normal architecture, sugges-
tive of polycystic kidney disease.
round nuclei and areas of degenerative cytologic atypia. 
These features can result in patches of tumor cells with large 
nuclei, irregular nuclear contours, and smudged chroma-
tin (12). They are usually unilateral and single amongst the 
general population but can present as multiple and bilateral 
in patients with TSC (77). While the significance of renal 
lesions in TSC is firmly established, little is known about 
predictable biomarkers. Renal oncocytomas are a more com-
mon cause of renal cell neoplasms in patients with TSC than 
in the general population (78). The diagnosis of renal onco-
cytoma should be confirmed by immunohistochemistry to 
avoid differential diagnosis with epithelioid AMLs.
Hypertension
Hypertension is a common secondary renal manifestation 
of TSC. Renal ischemia, growth of AML, and hyper secre-
tion of renin can lead to an increase in blood pressure, 
independent of family history (75). A study conducted 
by Kingswood et al. on TSC patients in the United King-
dom showed that the prevalence of hypertension was 23% 
amongst children aged <18 years and 11% amongst adults 
aged  >18 years  (75). Hypertension in TSC patients was 
secondary to renal involvement in the form of cysts and 
scarring, which predisposes to hypertensive crisis in these 
patients. If  treatment is not appropriately provided, hyper-
tension can accelerate renal scarring and loss of GFR. This 
high prevalence and consequence of improper management 
prompts the requirement of an effective strategy for blood 
pressure control in these patients. Since cystic changes in 
the kidney contribute to elevated blood pressure, the use of 
ACE-inhibitors or angiotensin receptor blockers (ARB) is 
recommended (15). These drugs prevent the production of 
Angiotensin-II and counteract aldosterone action, resulting 
in a decrease in blood pressure in addition to the prevention 
of remodeling effects of elevated pressure on the kidneys and 
heart (15).
Treatment
The first line of  treatment for AMLs are the use of  mTOR 
inhibitors given their ability to simultaneously reduce 
growth volume while preserving kidney function. In the 
presence of  large lesions, it is preferable to undergo treat-
ment through a pharmacological route as they often require 
extensive or repeat embolization, which can increase the risk 
of  chronic kidney disease (CKD) (79). The modification 
of  the upregulated mTOR pathway has been investigated 
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Table 5: Cystic subtypes seen in TSC.
Cystic disease type Characteristics Complications associated
TSC Polycystic A high frequency of mosaicism, and 
often these children have cystic disease on 
prenatal ultrasound.
Develops very significant disease by 2 months of age. 
Hypertension is often discovered by the second week 
of life but can take several months to develop. These 




Findings are subtle on MRI and can be 
missed on ultrasound.
Can develop into CKD stage 2 or 3 in the late teens or 
early 20s. Hypertension is not common until significant 
CKD develops
TSC Focal Cystic Appears as a cluster of cysts. The 
developmental timing can be in utero and 
only become phenotypically expressed 
after acute kidney injury.
Once expressed, it can result in rapid cyst formation and 
increased risk of hemorrhaging. 
TSC Cortical 
Cystic
Identified by cysts limited to the cortex 
and columns of Bertin. This cystic 
disease occurs early on and the cysts 
are remarkably uniform in size, at least 
during childhood
Present in large amounts and can be mistaken for 
glomerulocystic disease. 
TSC Multicystic Cysts can also be distributed throughout 
the cortical and medullary tissue and 
exhibit variable sizes with loss of 
corticomedullary differentiation.
Due to the variability of sizes, it can present varying 
degrees of risk from hemorrhaging. 
Adapted from Mulders YM. Large deletion causing the TSC2-PKD1 contiguous gene syndrome without infantile polycystic disease. J Med 
Genet. 2003;40(2):2–4 and Consugar MB, Wong WC, Lundquist PA, Rossetti S, Vickie J, (47) Walker DL, Rangel LJ, et al. Characteriza-
tion of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int. 
2009;74(11):1468–79. (75).
TSC, Tuberous sclerosis complex; MRI, magnetic resonance imaging; CKD, chronic kidney disease.
in a growing number of  clinical studies. The mTOR inhib-
itor, everolimus, is primarily used for patients who have 
multiple large angiolipomas that show evidence of  ≥5 mm 
of  growth per year and for patients who have had prior 
nephrectomy or embolization (44). With regard to AMLs, 
the first study demonstrating an antiproliferative effect of 
mTOR inhibitors was conducted in 20 patients. The results 
showed a significant reduction in AML size (80). The ben-
eficial effects subsided once treatment stopped, indicating 
a reversible effect of  mTOR inhibition. The EXIST-1 trial 
(n = 117) reported that 49% of  patients had ≥50% reduc-
tion in volume after a mean of  9.6 months of  treatment 
with everolimus (71). The Exist-2 trials found that after 24 
weeks, 55% of  patients receiving treatment showed >50% 
reduction in AML volume on 10 mg/day of  everolimus. 
Furthermore, AML vascularization was reduced with ever-
olimus treatment, providing an even more protective benefit 
through reduced risk of  aneurism. These results led to the 
approval for the use of  everolimus in the United States and 
Europe (81).
A similar drug, known as Sirolimus, is also very effective 
at significantly reducing the size of AMLs. Similar to everoli-
mus, the protective effects were lost when treatment was dis-
continued. For both treatment routes, the most frequent side 
effects were stomatitis, headache, hypercholesterolemia, uri-
nary tract infection, and amenorrhea, specifically in female 
patients (77). Furthermore, caution should be exercised in 
patients who have reduced renal function with estimated 
glomerular filtration rate (eGFR) of <45 mL/min/1.73 m2 at 
the onset of treatment. These patients are at risk for reduc-
tions in clearance, particularly if  they also present with pro-
teinuria. If  mTOR inhibitors are used for such patients, the 
eGFR should be assessed within 1 month of starting treat-
ment and every 4 months thereafter (82). Preclinical stud-
ies have shown that mTORC1 can contribute to the normal 
development of glomeruli and podocytes, while resulting in 
glomerular injury when decreased (82). Even kidneys with 
large renal AMLs can contribute significantly to renal func-
tion and should be treated primarily through pharmacologi-
cal means. Nephrectomy and embolism should be considered 
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Table 6: List of mTOR inhibitors trials.
Study N Study protocol Study outcome Complications
Bissler et al. 
2008 (70)
118 Double-blind, placebo-
controlled, phase 3 trial; 
patients aged 18 years or 
older with at least one 
angiomyolipoma of 3 cm 
were chosen to receive oral 
everolimus 10 mg per day or 
placebo. 
Response rate was 42% 
(33/79)
 >50% reduction in the 
growth of angiomyolipoma.
The most common adverse events 
in the everolimus and placebo 
groups were stomatitis (48%), 
nasopharyngitis (24%), and acne-
like skin lesions (22%).
Davies et al. 
2011 (83)
16 Multicenter phase 2 
nonrandomized open label trial. 
Dosage given to achieve steady-
state blood level of 3 to  
10 ng/mL.
Angiomyolipoma size was 
reduced in all 16 patients 
and by 30% or more in eight 
patients.
The most common side effects 
seen were oral mucositis (6 of 16 
patients), respiratory infections (5 





36  Daily sirolimus 10 mg/day. Overall response rate was 
44.4%; 16/36 had a partial 
response.
Mean decrease in kidney 
tumor size was 29.9% at 
week 52.
Adverse effects that occurred at 
a frequency of >20% included 
stomatitis, hypertriglyceridemia, 
hypercholesterolemia, bone 
marrow suppression (anemia, 
mild neutropenia, leucopenia), 
proteinuria, and joint pain.
Kingswood 
et al. 2013 
(15)
44 4.5 mg/m2/day everolimus to 
achieve target blood trough: 
5–15 ng/mL.
Angiomyolipoma response 
rates were 53.3% (16/30) in 
the everolimus arm.
Mouth ulceration, convulsion, 
stomatitis, fatigue and rash were 
the most common adverse effects 
with everolimus therapy, with 
rates of 43%, 30%, 26.7%, and 
20%, respectively.
Franz et al. 
2012 (71)
117 Double-blind, placebo-
controlled, phase 3 trial; 
patients were given oral 
everolimus 4·5 mg/m (2) per 
day (titrated to achieve blood 
trough concentrations of 5–15 
ng/mL) or placebo.
27 (35%) patients in the 
everolimus group had at 
least 50% reduction in the 
volume of subependymal 
giant cell astrocytomas.
The most common adverse events 
were mouth ulceration (32%) in 
the everolimus group, stomatitis 
(31%), and convulsion (23%).
Bissler 2013 
(81) 
20 Subjects will resume the dosing 
regimen that they were receiving 
at the completion of the initial 
RAD001 study (Bissler 2008).
N/A, results not posted





17 Four-month, prospective open-
label, single-arm study.
Initial dose of rapamycin (1 
mg/d). Doses were increased by 
1 mg every 2 weeks until stable 
plasma levels (4–8 ng/mL) were 
achieved.
58.8% (10/17) patients 
successfully had 50% AML 
volume reduction. After 
6 months, mean volume 
decrease was 55.18%, and 1 
year it was 66.38%.
No serious adverse effects were 
seen with oral aphthous ulcers 
(29.4%), hypertriglyceridaemia 
(29.4), diarrhea (17.6%), 
acneiform rash (11.8%), with 
microcytosis and hypochromia 
(17.6%) being the mild adverse 
effects seen.
mTOR, mammalian target of rapamycin; AML, angiomyolipoma.
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abilities of TOR-KI (89, 90). A polyethylene glycol unit 
connects the rapamycin-binding domain to FKBP12 along 
with the FRB domain of mTOR. This interaction leads to 
high selectivity of rapamycin to mTORC1 along with the 
kinase-inhibiting domain MLN0128 binding to the ATP site 
of mTORC1. Rapalink-1 has been found to be effective at 
inhibiting mTORC1 and mTORC2 downstream targets at 
doses as low as 1 and 3 nM in early clinical trials. While the 
full mechanism has not been elucidated, early results show 
its effectiveness in suppressing catalytic activity mTORC 
 components (86).
Prognosis of renal manifestations of TSC
The prognosis of patients with TSC is dependent on the 
severity and scope of symptoms that they develop. All 
patients are at risk for life-threatening conditions related to 
brain tumors, kidney lesions, or LAM. Regardless of the 
stage and severity of the conditions, continued monitoring 
and imaging is crucial for developing an appropriate treat-
ment plan. Appropriate medical intervention can allow 
most patients to have normal life expectancy with minimal 
loss of function. In rare cases, infections or tumors in vital 
organs can lead to severe issues and death. Patients with 
medium (4–8 cm) and large (>8 cm) AMLs are most at risk 
for injury or death (91). In these situations, early initiation 
of mTOR treatment can reverse growth and lessen the strain 
on the renal system and secondary organ systems. In a ret-
rospective study by Amin et al., the majority of deaths in 
TSC were attributed to renal issues. Of those that died due 
to renal issues, 62.5% died due to hemorrhaging of AMLs or 
RCC. The remaining patients died due to complications from 
CKD and polycystic kidney disease. While this study was 
conducted after the widespread use of mTOR inhibitors, the 
clinical studies mentioned previously show that their contin-
ued use can improve the expected prognosis of these patients 
and mitigate the loss of renal function (61).
Future perspective
In terms of future research, long-term studies are necessary 
to entirely ameliorate the long-term renal effects of mTOR 
inhibitors. While current safety profiles do not project a large 
percentage of serious adverse effects, long-term maintenance 
needs to be studied in order to better understand if  changes 
in dosage must be made. Furthermore, more research must 
be done in elucidating the full pathogenesis of the TSC path-
way to better understand the effects of hormones on the 
development of AMLs and how this may account for the 
difference in manifestation between male and female presen-
tation of AMLs. More research into gene therapy might also 
be the method to restore function in the absence of pharma-
cological therapy or a potential cure.
primarily in emergent situations in order to avoid any unnec-
essary renal damage (82). A summary of mTOR inhibitor 
trials are shown in Table 6.
New and Experimental Therapies
While mTOR inhibitors alone have shown to be effective 
treatment options, second-generation therapy options are 
being developed in order to improve efficacy and clinical 
outcomes. One example is that of dual PI3K/mTOR inhib-
itors. Currently, rapamycin inhibitors work as incomplete 
inactivators of mTORC1. However, they can simultaneously 
stimulate feedback activation of PI3K/Akt mitogenic path-
ways (86). Dual P13K/mTOR inhibitors work as competitive 
inhibitors that bind to the ATP-binding site on the catalytic 
site of both mTORC1/2 and PI3K, which are two crucial 
signaling hubs (87). New dual PI3K/mTOR inhibitors have 
been developed and pushed into phase 1 and 2 trials. How-
ever, in spite of the potential, clinical studies thus far have 
shown limited efficacy and significant concern of adverse 
effects, including nausea, diarrhea, vomiting, hyperglycemia, 
cutaneous rash, elevated liver enzyme levels, renal failure, 
and hypertension (86). Further trials will need to be con-
ducted to establish the limit of their use and the appropriate 
stage of treatment at which they should be introduced.
ATP-competitive inhibitors: TOR-KIs
Second-generation mTOR inhibitors that directly target and 
block the ATP catalytic site of both mTOR complexes are 
being developed. This results in widespread inhibition of the 
mTOR signal (88). These drugs are found to be more spe-
cific than the current inhibitors due to lower half-maximal 
inhibitory concentration (IC50) against mTOR activity than 
PI3K (88). The specificity allows for reduced risk of adverse 
effects associated with dual PI3K/mTOR inhibitors (86). In 
cell models, TOR-KIs have also shown to be effective anti-
proliferators against cells with insensitivity to first-generation 
mTOR inhibitors (25). Multiple TOR-KIs have undergone 
clinical trials with regard to neoplastic disorders. Sadly, 
mechanisms of resistance have been observed for this class as 
well in part due to the ability of PI3K/Akt/mTOR pathway 
to adjust in the face of change to individual components (86).
New generation: RapaLink-1
The third generation of drugs, known as RapaLink-1, is 
being developed in order to improve the efficacy, and to 
reduce resistance mechanisms and the incidence of side 
effects. By binding both the adenosine triphosphate (ATP) 
and the FKBP-rapamycin-binding (FRB) binding sites of 
mTOR, RapaLink-1 combines the strong affinity qualities 
of rapamycin for mTORC along with the kinase-inhibiting 
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Conclusion
TSC is a systemic and/or organ-specific disorder that man-
ifests on the kidney, heart, lungs, and brain in the form of 
skin lesions. Proper understanding of the TSC1/2 pathway 
and how its downstream effects lead to the development of 
tumors are paramount for understanding the pathogenesis 
of TSC and for developing new techniques for treating this 
disorder. An understanding of the renal manifestations, cur-
rent treatment, and diagnosis can allow physicians to better 
tackle these cases when they arise.
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